NO20050619L - Strukturelle korotenoid analoger for inhibisjon og lindring av sykdom - Google Patents

Strukturelle korotenoid analoger for inhibisjon og lindring av sykdom

Info

Publication number
NO20050619L
NO20050619L NO20050619A NO20050619A NO20050619L NO 20050619 L NO20050619 L NO 20050619L NO 20050619 A NO20050619 A NO 20050619A NO 20050619 A NO20050619 A NO 20050619A NO 20050619 L NO20050619 L NO 20050619L
Authority
NO
Norway
Prior art keywords
analog
combination
administered
relief
inhibition
Prior art date
Application number
NO20050619A
Other languages
English (en)
Norwegian (no)
Inventor
Sean O'malley
David G Watumull
Laura M Hix
Henry Jackson
Samuel Fournier Lockwood
Geoff Nadolski
Original Assignee
Hawaii Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hawaii Biotech Inc filed Critical Hawaii Biotech Inc
Publication of NO20050619L publication Critical patent/NO20050619L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/24—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by six-membered non-aromatic rings, e.g. beta-carotene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Biotechnology (AREA)
NO20050619A 2002-07-29 2005-02-03 Strukturelle korotenoid analoger for inhibisjon og lindring av sykdom NO20050619L (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US39919402P 2002-07-29 2002-07-29
US46797303P 2003-05-05 2003-05-05
US47283103P 2003-05-22 2003-05-22
US47374103P 2003-05-28 2003-05-28
US48530403P 2003-07-03 2003-07-03
PCT/US2003/023706 WO2004011423A2 (en) 2002-07-29 2003-07-29 Structural carotenoid analogs for the inhibition and amelioration of disease

Publications (1)

Publication Number Publication Date
NO20050619L true NO20050619L (no) 2005-04-27

Family

ID=31192475

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050619A NO20050619L (no) 2002-07-29 2005-02-03 Strukturelle korotenoid analoger for inhibisjon og lindring av sykdom

Country Status (12)

Country Link
US (5) US7145025B2 (US20050075337A1-20050407-C00001.png)
EP (2) EP1532108B1 (US20050075337A1-20050407-C00001.png)
JP (2) JP4601549B2 (US20050075337A1-20050407-C00001.png)
KR (1) KR20050069975A (US20050075337A1-20050407-C00001.png)
CN (2) CN1708480B (US20050075337A1-20050407-C00001.png)
AU (1) AU2003256982A1 (US20050075337A1-20050407-C00001.png)
BR (1) BRPI0313155B8 (US20050075337A1-20050407-C00001.png)
CA (1) CA2495167C (US20050075337A1-20050407-C00001.png)
HK (2) HK1084380A1 (US20050075337A1-20050407-C00001.png)
MX (1) MXPA05001202A (US20050075337A1-20050407-C00001.png)
NO (1) NO20050619L (US20050075337A1-20050407-C00001.png)
WO (1) WO2004011423A2 (US20050075337A1-20050407-C00001.png)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002336650B2 (en) 2001-10-25 2008-06-05 Emory University Catheter for modified perfusion
US20070160645A1 (en) * 2001-10-25 2007-07-12 Jakob Vinten-Johansen PostConditioning System And Method For The Reduction Of Ischemic-Reperfusion Injury In The Heart And Other Organs
US7351844B2 (en) * 2002-02-25 2008-04-01 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
US7320997B2 (en) * 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US20050009788A1 (en) * 2002-07-29 2005-01-13 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling connexin 43 expression
US20050049248A1 (en) * 2002-07-29 2005-03-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
US7375133B2 (en) * 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050004235A1 (en) * 2002-07-29 2005-01-06 Lockwood Samuel Fournier Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
WO2004011423A2 (en) 2002-07-29 2004-02-05 Hawaii Biotech, Inc. Structural carotenoid analogs for the inhibition and amelioration of disease
US20050059635A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
US7345091B2 (en) * 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050059659A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling C-reactive protein levels
US7763649B2 (en) * 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
US20050026874A1 (en) * 2002-07-29 2005-02-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
US7723327B2 (en) * 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
EP1753708B1 (en) * 2004-01-20 2018-02-21 Brigham Young University Novel sirtuin activating compounds and methods for making the same
EP1750723A1 (en) * 2004-04-14 2007-02-14 Hawaii Biotech, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US20060088904A1 (en) * 2004-10-01 2006-04-27 Lockwood Samuel F Methods for the synthesis of astaxanthin
JP2007238441A (ja) * 2004-12-03 2007-09-20 Fuji Chem Ind Co Ltd アスタキサンチンを有効成分とする体脂肪減少用組成物
JP2008525468A (ja) * 2004-12-22 2008-07-17 エモリー・ユニバーシティ ポストコンディショニング臓器保護作用を増強する治療補助薬
US20060270589A1 (en) * 2005-02-22 2006-11-30 Lockwood Samuel F Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of visual disabilities
JP2008531582A (ja) 2005-02-24 2008-08-14 ディフュージョン・ファーマシューティカルズ・エルエルシー トランスカロテノイド、それらの合成、配合、および使用
CA2606329A1 (en) * 2005-03-09 2006-09-21 Cardax Pharmaceuticals, Inc. Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders
EP1866428A2 (en) 2005-03-18 2007-12-19 Microbia, Inc. Production of carotenoids in oleaginous yeast and fungi
US20070015735A1 (en) * 2005-03-23 2007-01-18 Lockwood Samuel F Water-dispersible carotenoids, including analogs and derivatives
EP1874289A2 (en) * 2005-03-29 2008-01-09 Cardax Pharmaceuticals, Inc. Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
JP2006016407A (ja) * 2005-06-15 2006-01-19 Yamaha Motor Co Ltd ホスホジエステラーゼ阻害剤
JP2006016408A (ja) * 2005-06-23 2006-01-19 Yamaha Motor Co Ltd 血中中性脂肪抑制剤
EP1957057A1 (en) * 2005-12-07 2008-08-20 Cardax Pharmaceuticals, Inc. Structural carotenoid analogs or derivatives for the modulation of systemic and/or target organ redox status
JP2007153845A (ja) * 2005-12-07 2007-06-21 Yamaha Motor Co Ltd 脂肪蓄積抑制剤
US20070135521A1 (en) * 2005-12-14 2007-06-14 Yamaha Hatsudoki Kabushiki Kaisha Agent for Preventing Metabolic Syndrome
WO2007090095A2 (en) * 2006-01-27 2007-08-09 Cardax Pharmaceuticals, Inc. Synthesis of carotenoid analogs or derivatives with improved antioxidant characteristics
WO2007147163A2 (en) * 2006-06-16 2007-12-21 Cardax Pharmaceuticals, Inc. Compositions comprising carotenoid analogs or derivatives and methods for synthesis
BRPI0716644A2 (pt) * 2006-08-08 2013-10-15 Nestec Sa Composições estáveis e biodisponíveis de isômeros de carotenóides para pele e cabelo
US8691555B2 (en) 2006-09-28 2014-04-08 Dsm Ip Assests B.V. Production of carotenoids in oleaginous yeast and fungi
ITMI20061874A1 (it) * 2006-09-29 2006-12-29 Rosario Ammirante Composizione per il trattamento degli stati patologici neurodegenerativi del sistema nervoso centrale ed in particolare nel morbo di parkinson
WO2008118862A1 (en) * 2007-03-23 2008-10-02 Cardax Pharmaceuticals, Inc. Carotenoid analogs and derivatives for the prevention of platelet aggregation
EA200970944A1 (ru) * 2007-04-13 2010-06-30 Диффьюжн Фармасьютикалз Ллс Применение биполярных транскаротиноидов в качестве предварительного лечения при лечении заболевания периферических сосудов
MX2010004803A (es) * 2007-10-31 2010-09-09 Diffusion Pharmaceuticals Llc Una nueva clase de composiciones terapeuticas que mejoran la difusion de moleculas pequeñas.
JP2010270095A (ja) * 2008-05-30 2010-12-02 Yamaha Motor Co Ltd 認知行動能力向上剤
WO2010120686A2 (en) * 2009-04-13 2010-10-21 Parsons J Kellogg Methods for the diagnosis and treatment of benign prostatic hyperplasia
CA2765697C (en) * 2009-06-22 2019-11-12 Diffusion Pharmaceuticals Llc Diffusion enhancing compounds and their use alone or with thrombolytics
AU2010293065B2 (en) * 2009-09-11 2016-05-05 Nestec S.A. Compositions and methods for enhancing cognitive and related functions in animals
US8541645B2 (en) * 2009-10-22 2013-09-24 University Of Calcutta Animal model for cigarette-smoke-induced atherosclerosis and related methods
EP2575487B1 (en) 2010-06-02 2017-10-18 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
WO2012017033A1 (en) * 2010-08-04 2012-02-09 Ieo-Istituto Europeo Di Oncologia S.R.L. Method of antigen loading for immunotherapy
CN102389407A (zh) * 2011-12-01 2012-03-28 滨州医学院 虾青素在制备治疗和预防肺纤维化的药品中的应用
GB201120772D0 (en) * 2011-12-02 2012-01-11 Ip Science Ltd Cocoa-based food products
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
WO2014011676A1 (en) * 2012-07-09 2014-01-16 Tolleth Robert J Prevention of alcohol reaction with dietary supplements
CN103073471B (zh) * 2013-01-30 2014-11-05 江苏省农业科学院 一种叶黄素二琥珀酸酯的超声辅助合成方法
US9482675B1 (en) * 2013-07-31 2016-11-01 University Of Kentucky Research Foundation Methods and systems for prognosis and diagnosis of brain damage
JP6183746B2 (ja) * 2013-11-13 2017-08-23 国立大学法人高知大学 遅延性アレルギー抑制剤
EP3147279A4 (en) 2014-05-20 2018-01-10 Fuji Chemical Industry Co., Ltd. Carotenoid derivative, pharmaceutically acceptable salt thereof, and pharmaceutically acceptable ester or amide thereof
WO2016063278A1 (en) * 2014-10-19 2016-04-28 Shenkar College Of Engineering And Design Astaxanthin based polymer and uses thereof
JP6983660B2 (ja) 2015-05-08 2021-12-17 スペクトラル プラットフォームス インコーポレイテッド アルブミンに基づく非共有結合性複合体およびその使用方法
US20160367620A1 (en) 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione
US9572783B1 (en) * 2015-10-08 2017-02-21 Chuen Wei Lu Use of xanthophylls for the treatment of cancers
CN105646869B (zh) * 2016-01-04 2018-01-16 中国海洋大学 一种水溶性虾青素衍生物及其制备方法
KR20230014850A (ko) * 2016-03-24 2023-01-30 디퓨젼 파마슈티컬즈 엘엘씨 암을 치료하기 위한, 화학 요법 및 방사선 요법과의 양극성 트랜스 카로티노이드의 용도
CN106748946A (zh) * 2017-02-14 2017-05-31 烟台固特丽生物科技股份有限公司 一种含水溶性虾青素作物营养液的制备方法
US11105747B2 (en) 2017-03-20 2021-08-31 Spectral Platforms, Inc. Spectroscopic methods to detect and characterize microorganisms
US20210283055A1 (en) * 2018-05-03 2021-09-16 L.E.A.F. Holdings Group Llc Carotenoid compositions and uses thereof
JP2021176821A (ja) * 2018-08-01 2021-11-11 アスタファーマシューティカルズ株式会社 新規カロテノイド関連誘導体、その塩又はエステル類若しくはアミド類
CN109678771A (zh) * 2018-12-28 2019-04-26 广州立达尔生物科技股份有限公司 一种叶黄素甘氨酸酯及其盐酸盐的制备方法
US20220380306A1 (en) * 2019-09-27 2022-12-01 Cardax,Inc. Astaxanthin esters and methods of use thereof
FR3105790B1 (fr) * 2019-12-26 2022-01-14 Biophytis Composés chimiques ciblant l’œil et leur utilisation dans le traitement de maladies oculaires
CN111257466B (zh) * 2020-02-27 2022-04-01 南宁海关技术中心 一种红心鸭蛋中类胡萝卜素含量的测定方法
CN113788867B (zh) * 2021-06-30 2023-12-26 东北林业大学 一种叶黄素水溶性衍生物及其制备工艺
DE102022134274A1 (de) 2022-12-21 2024-06-27 Endress+Hauser Conducta Gmbh+Co. Kg Sensorelement für einen optochemischen Sensor
CN118084755A (zh) * 2024-04-22 2024-05-28 潍坊富邦药业有限公司 一种高水溶性虾青素衍生物及制备方法
CN118108646A (zh) * 2024-04-22 2024-05-31 潍坊富邦药业有限公司 一种水溶性虾青素衍生物及其制备方法
CN118063368A (zh) * 2024-04-22 2024-05-24 潍坊富邦药业有限公司 一种水溶性虾青素衍生物及其合成方法

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH314001A (de) * 1952-12-18 1956-05-31 Hoffmann La Roche Verfahren zur Herstellung von Vitamin-A-Estern
CH420822A (de) * 1960-10-17 1966-09-15 Hoffmann La Roche Wasserdispergierbare Carotinoidzubereitung
US3354218A (en) * 1963-05-10 1967-11-21 Hoffmann La Roche Process for preparing 4-(2, 6, 6-trimethyl-4-methoxy-1-cyclohexen-1-yl)-3-buten-2-one
FR2076448A5 (US20050075337A1-20050407-C00001.png) 1970-01-15 1971-10-15 Rhone Poulenc Sa
US3853993A (en) * 1973-05-01 1974-12-10 Univ Virginia Process for increasing oxygen diffusivity and method for treating atherosclerosis
US3788468A (en) * 1973-05-01 1974-01-29 Univ Virginia Process for increasing oxygen diffusivity
US3989757A (en) 1973-08-29 1976-11-02 Hoffmann-La Roche Inc. Isomerizing cis-carotenoids to all-trans-carotenoids
CH609320A5 (US20050075337A1-20050407-C00001.png) * 1974-06-20 1979-02-28 Hoffmann La Roche
US3965261A (en) 1975-04-29 1976-06-22 University Of Virginia Method for treating papillomas
US3975519A (en) 1975-06-09 1976-08-17 University Of Virginia Method for increasing the oxygen partial pressure in the bloodstream of mammals
US4070460A (en) 1975-11-10 1978-01-24 University Of Virginia Patents Foundation Method for treating cerebral edema
US4009270A (en) 1975-11-21 1977-02-22 The University Of Virginia Method for treating spinal cord injury
CH623304A5 (US20050075337A1-20050407-C00001.png) * 1975-11-30 1981-05-29 Hoffmann La Roche
US4038144A (en) 1976-04-19 1977-07-26 The University Of Virginia Method of increasing fermentation yields
US4046880A (en) 1976-04-20 1977-09-06 The University Of Virginia Method of treating hypertension
JPS6053031B2 (ja) 1978-03-31 1985-11-22 武田薬品工業株式会社 スピロ化合物およびその製造方法
US4176179A (en) 1978-04-17 1979-11-27 The University Of Virginia Alumni Patents Foundation Method for treating arthritis
DE2964401D1 (en) * 1978-06-02 1983-02-03 Hoffmann La Roche Process for the preparation of cyclohexenyl derivatives, and intermediates produced in the synthesis
EP0005749B1 (de) * 1978-06-02 1983-03-30 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Cyclohexenderivate, Verfahren zu deren Herstellung, sowie deren Verwendung
DE3048000A1 (de) 1980-12-19 1982-07-15 Basf Ag Stabile injizierbare (beta)-carotin-solubilisate und verfahren zu ihrer herstellung
EP0077439B1 (de) * 1981-10-16 1986-09-24 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Verfahren zur Herstellung von Cyclohexenderivaten, sowie ein neues Ausgangsprodukt und neue Zwischenprodukte in diesem Verfahren
ATE13666T1 (de) * 1982-02-09 1985-06-15 Hoffmann La Roche Verfahren zur herstellung von cyclohexenderivaten.
EP0101597B1 (de) * 1982-08-20 1988-06-22 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Verfahren zur Herstellung von Astaxanthin und Zwischenprodukten in der Astaxanthin-Synthese
US4491574A (en) 1983-03-02 1985-01-01 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Reduction of high dose aspirin toxicity by dietary vitamin A
ATE62414T1 (de) 1984-01-28 1991-04-15 Roshdy Ismail Mittel zur behandlung von herzerkrankungen.
US5346488A (en) 1985-04-08 1994-09-13 The General Hospital Corporation Laser-induced ablation of atherosclerotic plaque
US4851339A (en) * 1986-04-01 1989-07-25 Hills Christopher B Extraction of anti-mutagenic pigments from algae and vegetables
DK171297B1 (da) * 1987-03-27 1996-08-26 Hoffmann La Roche Fremgangsmåde til fremstilling af cyclohexenderivater som mellemprodukter til fremstilling af zeaxanthin samt cyclohexenderivater
US5057494A (en) 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
DK0410236T3 (da) 1989-07-25 1993-12-13 Hoffmann La Roche Fremgangsmåde til fremstilling af caratenoidpræparater
US5278189A (en) 1990-06-04 1994-01-11 Rath Matthias W Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A)
CA2093008A1 (en) 1990-10-01 1992-04-02 Charles H. Hennekens Beta-carotene and vitamin e therapy for inhibition of major vascular events
US6132790A (en) 1991-09-06 2000-10-17 Betatene Limited Carotenoid composition
CA2125888C (en) 1992-01-06 2002-08-27 Harry B. Demopoulos Pharmaceutically active antioxidant containing composition and the method of its use to prevent and treat restenosis following angioplasty
US5221668A (en) 1992-02-26 1993-06-22 Abbott Laboratories Nutritional product for trauma and surgery patients
IL104736A0 (en) 1992-03-27 1993-06-10 Zeagen Inc Method for producing beta-carotene using a fungal mated culture
US5328845A (en) 1992-03-27 1994-07-12 Universal Foods Corporation Fungal negative microorganism capable of producing high levels of beta-carotene
DK0565989T3 (da) 1992-04-14 1997-12-15 Hoffmann La Roche Præparater af fedtopløselige stoffer
US5310764A (en) 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene
US5612485A (en) 1992-06-04 1997-03-18 Betatene Ltd Of Cheltenham High cis beta-carotene composition
GB9219524D0 (en) 1992-09-15 1992-10-28 Smithkline Beecham Plc Novel composition
US5310554A (en) 1992-10-27 1994-05-10 Natural Carotene Corporation High purity beta-carotene
DE19609538A1 (de) 1996-03-11 1997-09-18 Basf Ag Feinverteilte Carotinoid- und Retinoidsuspensionen und Verfahren zu ihrer Herstellung
JPH08510995A (ja) 1993-03-22 1996-11-19 ベータティーン・リミテッド 水分散性治療用化合物
WO1994021231A1 (en) 1993-03-22 1994-09-29 Betatene Limited Therapeutic agent for the treatment of melanomas
DE69424719T2 (de) * 1993-06-24 2000-11-02 Hoffmann La Roche Pigmentierung mit Carotinoiden
US6218436B1 (en) 1993-06-28 2001-04-17 The Howard Foundation Pharmaceutically active carotenoids
DE4322277A1 (de) 1993-07-05 1995-01-12 Basf Ag Verbessertes Verfahren zur Herstellung von Astaxanthin, neue Zwischenprodukte hierfür sowie ein Verfahren zu deren Herstellung
FR2707184B1 (fr) 1993-07-08 1995-08-11 Rhone Poulenc Nutrition Animal Procédé de préparation de sphérules contenant un principe actif alimentaire ou pharmaceutique.
US5607839A (en) 1993-07-22 1997-03-04 Nippon Oil Company, Ltd. Bacteria belonging to new genus process for production of carotenoids using same
JP3249867B2 (ja) * 1993-10-21 2002-01-21 株式会社クラレ アスタキサンチンの製造方法
CH685189A5 (de) * 1993-11-19 1995-04-28 Marigen Sa Ultramikroemulsionen aus spontan dispergierbaren Konzentraten mit antitumoral wirksamen Xanthophyll-Estern.
US6428816B1 (en) 1994-04-08 2002-08-06 Cognis Australia Pty., Ltd. Carotenoid agent for inhibiting the conversion of epithelial cells to tumors
SE9401738D0 (sv) 1994-05-19 1994-05-19 Ewos Ab Bioactive feed
JPH0873312A (ja) * 1994-09-02 1996-03-19 Noevir Co Ltd 皮膚外用剤
SE503336C2 (sv) 1994-09-19 1996-05-28 Asta Carotene Ab Medel och sätt för att öka produktionen av/hos fjäderfän
US5527533A (en) 1994-10-27 1996-06-18 Board Of Trustees Of The University Of Illinois Method of retarding and ameliorating central nervous system and eye damage
ES2136786T3 (es) 1994-12-21 1999-12-01 Hoffmann La Roche Cetonas y esteres de carotenoides.
US5643943A (en) 1994-12-23 1997-07-01 Alcon Laboratories, Inc. Systemic administration of esters and amides of antioxidants which may be used as antioxidant prodrug therapy for oxidative and inflammatory pathogenesis
US5589468A (en) 1995-01-13 1996-12-31 Clintec Nutrition Co. Method for providing nutrition to elderly patients
US5886053A (en) 1995-02-03 1999-03-23 Basf Aktiengesellschaft Use of carotenoids for producing drugs for the treatment of dermatoses
US5532009A (en) * 1995-06-07 1996-07-02 The Procter & Gamble Company Fat substitutes containing water soluble beta-carotene
JPH08337592A (ja) * 1995-06-13 1996-12-24 Kaiyo Bio Technol Kenkyusho:Kk 新規カロテノイド
JPH0984591A (ja) * 1995-09-26 1997-03-31 Kaiyo Bio Technol Kenkyusho:Kk カロテノイド硫酸エステルおよびその製造方法
US6060511A (en) 1995-10-05 2000-05-09 Gainer; John L. Trans-sodium crocetinate, methods of making and methods of use thereof
DE69637277T2 (de) 1995-10-17 2008-05-08 Showa Denko K.K. Hochreine tocopherolphosphate, verfahren zu ihrer herstellung und analyse, und kosmetika
JPH09124470A (ja) 1995-10-26 1997-05-13 Suntory Ltd 抗ストレス組成物
US5854015A (en) 1995-10-31 1998-12-29 Applied Food Biotechnology, Inc. Method of making pure 3R-3'R stereoisomer of zeaxanthin for human ingestion
US5827539A (en) 1995-12-28 1998-10-27 Amway Corporation Dry carotenoid-oil powder and process for making same
US5837224A (en) 1996-01-19 1998-11-17 The Regents Of The University Of Michigan Method of inhibiting photoaging of skin
US6232060B1 (en) 1996-01-19 2001-05-15 Galileo Laboratories, Inc. Assay system for anti-stress agents
JPH09202730A (ja) * 1996-01-24 1997-08-05 Nippon Mektron Ltd 発ガン抑制作用剤
US5801159A (en) 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
DE19609477A1 (de) 1996-03-11 1997-09-18 Basf Ag Stabile wäßrige Solubilisate von Carotinoiden und Vitamine
DE19609476A1 (de) 1996-03-11 1997-09-18 Basf Ag Stabile zur parenteralen Verabreichung geeignete Carotinoid-Emulsionen
SE506191C2 (sv) 1996-03-27 1997-11-17 Astacarotene Ab Medel och sätt för att öka produktionen av/hos däggdjur
EP0807431B1 (en) 1996-05-14 2004-03-24 DSM IP Assets B.V. Process for the manufacture of carotenoid compositions
DE19637517A1 (de) 1996-09-13 1998-03-19 Basf Ag Herstellung von pulverförmigen, kaltwasserdispergierbaren Carotinoid-Zubereitungen und die Verwendung der neuen Carotinoid-Zubereitungen
DE19649062A1 (de) 1996-11-27 1998-05-28 Basf Ag Flüssige, mit Öl mischbare Carotinoid-Zubereitungen
US20020032176A1 (en) * 1996-12-25 2002-03-14 Takashi Maoka Carcinogenesis inhibitors
PT1493439E (pt) 1997-04-02 2012-01-10 Brigham & Womens Hospital Meio de avaliação do perfil de risco de um indivíduo para uma doença aterosclerótica
US5858700A (en) 1997-04-03 1999-01-12 Kemin Foods, Lc Process for the isolation and purification of lycopene crystals
AU752468B2 (en) * 1997-04-04 2002-09-19 Phyllis E. Bowen Lutein esters having high bioavailability
US5811446A (en) 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US5876782A (en) 1997-05-14 1999-03-02 Kemin Industries, Inc. Method for the conversion of xanthophylls in plant material
JPH10327865A (ja) * 1997-05-29 1998-12-15 Kirin Brewery Co Ltd カロテノイド配糖体およびその製造法
SE512531C2 (sv) 1997-09-04 2000-03-27 Astacarotene Ab Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur
US6008417A (en) 1997-10-20 1999-12-28 Roche Vitamins Inc. Process for making metabolites of lycopene
US5959138A (en) * 1997-11-25 1999-09-28 Industrial Organica S.A. De C.V. Short chain diesters and process for making the same
SE511237C2 (sv) 1997-12-16 1999-08-30 Astacarotene Ab Användning av åtminstone en typ av xantofyller för framställning av ett humant eller verinärmedicinskt läkemedel för profylaktisk behandling av mastit hos däggdjursmammor
DE19802134A1 (de) * 1998-01-21 1999-07-22 Basf Ag Verwendung von Carotinoid-Aggregaten als Färbemittel
US6020003A (en) 1998-02-23 2000-02-01 Basf Corporation Method of making spray-dried powders with high edible-oil loadings based on non-hydrolyzed gelatin
US6051587A (en) 1998-04-16 2000-04-18 Medicure, Inc. Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
US6043259A (en) 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
NL1010351C2 (nl) * 1998-10-19 2001-01-08 Werklust & Beheer B V Esters van caroteno´den voor gebruik in de preventie en behandeling van oogaandoeningen.
US6075058A (en) 1998-12-12 2000-06-13 Tufts University Compositions for increased bioavailability of carotenoids
US6399105B1 (en) 1999-01-20 2002-06-04 Peter Donald Collin Sea cucumber carotenoid lipid fraction products and methods of use
JP4491090B2 (ja) * 1999-10-08 2010-06-30 ヒガシマル醤油株式会社 アポトーシス誘導剤
US6426362B1 (en) 1999-10-08 2002-07-30 Galileo Laboratories, Inc. Formulations of tocopherols and methods of making and using them
EP1238068A1 (en) 1999-12-08 2002-09-11 California Institute Of Technology Directed evolution of biosynthetic and biodegration pathways
US6344214B1 (en) 1999-12-13 2002-02-05 Cyanotech Corporation Method for retarding and ameliorating fever blisters and canker sores
US6258855B1 (en) 2000-02-08 2001-07-10 Cyanotech Corporation Method of retarding and ameliorating carpal tunnel syndrome
WO2001076588A1 (en) 2000-04-06 2001-10-18 Coastside Research Method to inhibit lipoxygenase and cancer cell proliferation
US20030104090A1 (en) 2000-05-05 2003-06-05 Levy Pedro E. Supplements containing annatto extracts and carotenoids and methods for using the same
US6579544B1 (en) 2000-05-31 2003-06-17 Nutriex, L.L.C. Method for supplementing the diet
US20020110604A1 (en) 2000-08-11 2002-08-15 Ashni Naturaceuticals, Inc. Composition exhibiting synergistic antioxidant activity
AU2002221934A1 (en) 2000-12-16 2002-06-24 Aventis Pharma Deutschland Gmbh Health promoting compositions
WO2002068385A2 (en) 2001-02-23 2002-09-06 Barlovento International Novel carotenoid esters
US6984523B2 (en) 2001-08-02 2006-01-10 E.I. Du Pont De Nemours And Company Carotenoid ketolase gene
GB0119052D0 (en) 2001-08-03 2001-09-26 Mars Uk Ltd Foodstuff
ES2297125T5 (es) * 2002-02-06 2013-07-03 Dsm Ip Assets B.V. Ésteres de astaxantina
US7514107B2 (en) 2002-03-21 2009-04-07 Mars, Incorporated Treatment of diseases involving defective gap junctional communication
SG150385A1 (en) * 2002-04-30 2009-03-30 Suntory Ltd Astaxanthin medium-chain fatty acid ester, production method of the same, and composition comprising the same
US20050143475A1 (en) 2002-07-29 2005-06-30 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US20050004235A1 (en) 2002-07-29 2005-01-06 Lockwood Samuel Fournier Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
US7375133B2 (en) 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
WO2004011423A2 (en) 2002-07-29 2004-02-05 Hawaii Biotech, Inc. Structural carotenoid analogs for the inhibition and amelioration of disease
US7723327B2 (en) 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
US20050009788A1 (en) 2002-07-29 2005-01-13 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling connexin 43 expression
US20050059635A1 (en) 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
US20050026874A1 (en) 2002-07-29 2005-02-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
US20050049248A1 (en) 2002-07-29 2005-03-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
US7320997B2 (en) 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US7521584B2 (en) 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US7345091B2 (en) 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US7763649B2 (en) 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
US20050059659A1 (en) 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling C-reactive protein levels
US20050148517A1 (en) * 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
EP1750723A1 (en) * 2004-04-14 2007-02-14 Hawaii Biotech, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US20060088904A1 (en) * 2004-10-01 2006-04-27 Lockwood Samuel F Methods for the synthesis of astaxanthin

Also Published As

Publication number Publication date
EP2392562B1 (en) 2018-03-07
KR20050069975A (ko) 2005-07-05
JP2006517197A (ja) 2006-07-20
US20050037995A1 (en) 2005-02-17
CN101845009A (zh) 2010-09-29
WO2004011423A3 (en) 2004-05-06
US20040162329A1 (en) 2004-08-19
US20050075337A1 (en) 2005-04-07
MXPA05001202A (es) 2005-11-23
JP5187700B2 (ja) 2013-04-24
BRPI0313155B1 (pt) 2018-11-06
JP2010248243A (ja) 2010-11-04
JP4601549B2 (ja) 2010-12-22
CN1708480A (zh) 2005-12-14
WO2004011423A2 (en) 2004-02-05
US7145025B2 (en) 2006-12-05
HK1148997A1 (en) 2011-09-23
US20060229446A1 (en) 2006-10-12
BRPI0313155B8 (pt) 2021-05-25
AU2003256982A1 (en) 2004-02-16
US7592449B2 (en) 2009-09-22
CA2495167C (en) 2018-08-21
CN1708480B (zh) 2010-12-15
HK1084380A1 (en) 2006-07-28
EP2392562A1 (en) 2011-12-07
EP1532108A2 (en) 2005-05-25
CN101845009B (zh) 2012-10-03
CA2495167A1 (en) 2004-02-05
BR0313155A (pt) 2005-07-12
US20050065097A1 (en) 2005-03-24
EP1532108B1 (en) 2016-06-29
US7317008B2 (en) 2008-01-08

Similar Documents

Publication Publication Date Title
NO20050619L (no) Strukturelle korotenoid analoger for inhibisjon og lindring av sykdom
JP2019023245A (ja) スルホラファンまたはスルホラファン前駆体およびキノコ抽出物または粉末を含む組成物
JP5466403B2 (ja) 皮膚の炎症状態の治療用の植物水組成物
Bailly et al. Erinacine A and related cyathane diterpenoids: Molecular diversity and mechanisms underlying their neuroprotection and anticancer activities
Athiroh et al. Antioxidative and blood pressure-lowering effects of Scurrula atropurpurea on deoxycorticosterone acetate–salt hypertensive rats
NO20053077L (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
KR20120047240A (ko) 주사 또는 홍안 관련 피부 질환의 치료를 위한, 베르베린 또는 그의 유사체를 함유하는 조성물
HK1083196A1 (en) Topical compositions having a natural ingredient and method of use
CN116249683A8 (zh) 氘甲基取代吡嗪并吡嗪并喹啉酮类衍生物、其制备方法及其在医药上的应用
JPH0517365A (ja) テストステロン ５α−レダクターゼ阻害剤
US20120316144A1 (en) Antifungal agent
KR20070056207A (ko) 포도근 추출물을 함유하는 테스토스테론 5알파-리덕타아제저해제
WO2006022762B1 (en) Compositions and methods for the management of hyperproliferative dermatological conditions
KR20070074690A (ko) 향유 추출물을 함유하는 테스토스테론 5알파-리덕타아제저해제
Ali Use of acacia gum in the treatment of skin lesions of two children with Kwashiorkor
CA2489705A1 (en) Use of amide derivative of ge 2270 factor a3 for the treatment of acne
CN107072979A (zh) 类黄酮化合物在制备伤口愈合组合物的用途
Abdelhamid et al. Biochemical effects of basil and marjoram on ulcerative gastritis induced experimentally in rats
US11896611B1 (en) Phytochemical/ nutraceutical composition for multimodal prophylaxis against and treatment of viral and bacterial infection and inflammation
KR20170140791A (ko) 부종의 치료, 예방 또는 개선용 조성물
US11065229B2 (en) Method for reducing itching in atopic dermatitis
Patel et al. Study of the antinociceptive effect of neem leaf extract and its interaction with morphine in mice
Cheng et al. Polyphenols of Salvia miltiorrhiza in Aging-Associated Cardiovascular Diseases and Cancer
Rahangdale et al. A review on management of varius disease by traditional chinese medicine Ganoderma lucidum
EP3244873B1 (en) Cosmetic composition for oral administration for reinforcing the skin barrier.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application